The INMiND-02 Study is a new trial looking at whether a drug that is currently used to treat arthritis could help the memory function of people with Mild Cognitive Impairment (MCI).
What are the main aims of the INMiND-02 study?
To see if a drug (Etanercept) already used for the treatment of rheumatoid arthritis might stop people diagnosed with Mild Cognitive Impairment getting worse by dampening down inflammation in the brain.
It involves a participant with Mild Cognitive Impairment taking Etanercept or a placebo once per week and then being tested for memory problems four times over the course of a year. It also involves having three brains scans at the start and end of the study.
How long is the study for?
It is a year long study.
What do you hope the outcomes of the study will be?
We hope to see that participants taking Etanercept will show less decline in memory function and show a reduction in brain inflammation than those taking the placebo.
Where is the study based?
The study is based in Southampton and Manchester.